Lidocain-Egis

Lidocaine, the active ingredient in Lidocain‑Egis, is a local anesthetic presented as an oromucosal preparation for topical mucosal use. It provides temporary numbing of oral tissues to relieve pain associated with mucosal irritation, dental procedures, and related conditions.

GNH USA supplies Lidocain‑Egis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. It is manufactured under EU GMP guidelines and exported to multiple regions.

Lidocaine acts locally on oral mucosal tissues to provide analgesia for several common conditions.

Oral mucositis: reduces pain from chemotherapy‑induced mucosal lesions, allowing better nutrition and comfort. Dental procedures: provides temporary numbness of the oral mucosa to facilitate minor surgical or diagnostic work. Sore throat relief: alleviates discomfort associated with inflammatory throat conditions by numbing the affected area.

Lidocaine may cause local and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Taste alteration: temporary metallic or bitter taste in the mouth. - Burning sensation: mild burning or stinging at the application site. - Numbness: localized loss of sensation lasting a short period. - Dizziness: transient light‑headedness, especially with higher exposure.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis requiring immediate medical attention. - Methemoglobinemia: reduced oxygen‑carrying capacity of blood, presenting with cyanosis. - Cardiac toxicity: arrhythmias or conduction disturbances, particularly with excessive systemic absorption.

When using Lidocain‑Egis, consider the following precautions to minimize risk.

- Assess allergy: confirm no known hypersensitivity to lidocaine or related amide anesthetics. - Limit area: apply only to the intended mucosal surface and avoid excessive quantity. - Monitor systemic exposure: watch for signs of toxicity if large areas are treated or if used repeatedly. - Use with caution in cardiac patients: consider underlying conduction disorders before extensive use. - Avoid use with other local anesthetics: concurrent application may increase toxicity. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Lidocain‑Egis can interact with several medicines; awareness of these interactions helps prevent adverse effects.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase systemic lidocaine levels and risk of cardiac toxicity. - Other local anesthetics: additive nerve and cardiac toxicity when used together. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): can raise plasma concentrations of lidocaine.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardic effects when systemic absorption occurs. - Diuretics (e.g., furosemide): can alter plasma protein binding, affecting lidocaine activity. - Alcohol: concurrent use may increase central nervous system depression.